(31)P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3T.

[1]  Kieran Clarke,et al.  A comparison of cardiac 31P MRS at 1.5 and 3 T , 2008, NMR in biomedicine.

[2]  Xiao-Hong Zhu,et al.  Open‐chest 31P magnetic resonance spectroscopy of mouse heart at 4.7 Tesla , 2006, Journal of magnetic resonance imaging : JMRI.

[3]  Robert G. Weiss,et al.  Altered Creatine Kinase Adenosine Triphosphate Kinetics in Failing Hypertrophied Human Myocardium , 2006, Circulation.

[4]  K. Clarke,et al.  Modification of myocardial substrate use as a therapy for heart failure , 2006, Nature Clinical Practice Cardiovascular Medicine.

[5]  P. Scifo,et al.  Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. , 2006, European heart journal.

[6]  Paul A Bottomley,et al.  ATP flux through creatine kinase in the normal, stressed, and failing human heart. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P. Boesiger,et al.  Navigator gating and volume tracking for double‐triggered cardiac proton spectroscopy at 3 Tesla , 2004, Magnetic resonance in medicine.

[8]  Peter Boesiger,et al.  Cardiac SSFP imaging at 3 Tesla , 2004, Magnetic resonance in medicine.

[9]  S. Morikawa,et al.  Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[10]  Kieran Clarke,et al.  Abnormal Cardiac and Skeletal Muscle Energy Metabolism in Patients With Type 2 Diabetes , 2003, Circulation.

[11]  A. Blamire,et al.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. , 2003, Journal of the American College of Cardiology.

[12]  Peter Boesiger,et al.  Volume tracking cardiac 31P spectroscopy , 2002, Magnetic resonance in medicine.

[13]  S. Huffel,et al.  MR spectroscopy quantitation: a review of time‐domain methods , 2001, NMR in biomedicine.

[14]  D van Ormondt,et al.  Cramér–Rao bounds: an evaluation tool for quantitation , 2001, NMR in biomedicine.

[15]  P. Barker,et al.  Single‐voxel proton MRS of the human brain at 1.5T and 3.0T , 2001, Magnetic resonance in medicine.

[16]  G. Gong,et al.  High-Energy Phosphate Metabolism and Creatine Kinase in Failing Hearts: A New Porcine Model , 2001, Circulation.

[17]  J. Hoerter,et al.  Subcellular creatine kinase alterations. Implications in heart failure. , 1999, Circulation research.

[18]  K. Uğurbil,et al.  Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength. , 1998, Journal of magnetic resonance.

[19]  O. Lutz,et al.  31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. , 1998, Circulation.

[20]  B. Rajagopalan,et al.  Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. , 1998, Circulation.

[21]  S. Neubauer,et al.  Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. , 1997, Circulation.

[22]  S. Neubauer,et al.  Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy. , 1997, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[23]  K. Takeda,et al.  31P MR spectroscopy in hypertrophic cardiomyopathy: comparison with Tl-201 myocardial perfusion imaging. , 1993, American heart journal.

[24]  E. E. van der Wall,et al.  Cardiac metabolism in patients with dilated and hypertrophic cardio‐myopathy: Assessment with proton‐decoupled P‐31 MR spectroscopy , 1992, Journal of Magnetic Resonance Imaging.

[25]  G. Radda,et al.  Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy , 1991, The Lancet.

[26]  C. Hardy,et al.  Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. , 1990, The New England journal of medicine.

[27]  R. Ordidge,et al.  Re: Separate water and fat MR images. , 1985, Radiology.

[28]  P A Bottomley,et al.  Noninvasive study of high-energy phosphate metabolism in human heart by depth-resolved 31P NMR spectroscopy. , 1985, Science.

[29]  J. Ingwall,et al.  Reaction rates of creatine kinase and ATP synthesis in the isolated rat heart. A 31P NMR magnetization transfer study. , 1985, The Journal of biological chemistry.

[30]  D. Kass,et al.  Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice. , 2007, American journal of physiology. Heart and circulatory physiology.

[31]  M. Schocke,et al.  Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. , 2002, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.